{"type":"root","children":[{"type":"paragraph","children":[{"type":"text","value":"Cytokeratin MNF116 is a broad-spectrum anti-cytokeratin reacting with intermediate and low-molecular-weight keratins, ranging from 40 through 58 kD, corresponding to cytokeratin 5, 6, 8, 17 and 19. It shows a broad pattern of reactivity with human epithelial tissues from simple glandular epithelial to stratified squamous epithelia, like epidermis, mammary gland ducts, and tracheal epithelium."}]},{"type":"paragraph","children":[{"type":"text","value":"Cytokeratin MNF116 is a useful aid for the classification of neoplasms of epithelial origin including Squamous Cell Carcinoma, Small Cell Carcinoma, Sarcomatoid Carcinoma, Spindle Cell Carcinoma, Epithelioid and Spindle Cell component of Malignant Mesothelioma and Adenocarcinoma. A wide range of soft tissue tumors are also positive with cytokeratin MNF116: monophasic and biphasic Synovial Sarcoma, vascular neoplasms including Epithelioid Hemangioendothelioma, Epithelioid Angiosarcoma, Epithelioid Sarcoma. Desmoplastic Small Round Cell Tumors require cytokeratin positivity for diagnosis. Smooth muscle tumors and Plasmacytoma may demonstrate aberrant expression of cytokeratin MNF116."}]}]}